CMS sends Medicaid outpatient drug rule to OMB

By Virgil Dickson  |  August 27, 2015

The CMS has completed work on a long-awaited rule overhauling the way prescription drugs are purchased for Medicaid beneficiaries. The regulation has been submitted to the Office of Management and Budget for review.

States taking the lead in laws to curb drug costs

By Shannon Muchmore  |  August 27, 2015

Massachusetts has introduced legislation to require pricing transparency and allow some price caps. Six other states are following, all while Congress acknowledges that there's a problem but has yet to do anything about it.

Amgen wins approval for second biotech cholesterol drug

By Associated Press  |  August 27, 2015

Amgen has won approval for the second medicine in a new class of biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades.

Will biosimilars naming plan promote more competitive drug pricing?

Will biosimilars naming plan promote more competitive drug pricing?

By Steven Ross Johnson  |  August 27, 2015

Biosimilar drugs will carry a four-letter suffix on the nonproprietary names they share with brand-name biologic drugs, the Food and Drug Administration announced Thursday. It's a move that could determine how lower-cost alternatives compete against their original counterparts.

Pfizer says Hospira purchase will close in early September

By Associated Press  |  August 24, 2015

Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and infusion devicemaker Hospira, and says the deal will close in early September. The FTC has ordered Pfizer to sell four drugs in order to preserve competition.

Inovalon to acquire Avalere for $140M

By Aurora Aguilar and Joseph Conn  |  August 24, 2015

Inovalon, a publicly traded healthcare analytics company, has entered into a definitive agreement to acquire healthcare consulting firm Avalere Health.

CDC conference will tackle coping in 'post-antibiotic' era

By Michael Sandler and Sabriya Rice  |  August 22, 2015

The threat of a looming “post-antibiotic era” has been detailed for years in media reports, but the Centers for Disease Control and Prevention says the nation has finally reached that tipping point.

Fast-track voucher sells for record

By Steven Ross Johnson  |  August 22, 2015

United Therapeutics Corp. recently sold a record-setting $350 million voucher for fast-track Food and Drug Administration review to AbbVie. The secondary market for the vouchers highlights the industry's growing thirst to get to market with the next potential blockbuster therapy.

Female sex pill spurs new questions

Female sex pill spurs new questions

By Steven Ross Johnson  |  August 22, 2015

The Food and Drug Administration's recent approval of Addyi, the first drug to increase sexual desire in women, could lead to some new and complicated conversations in doctors' offices across the country.

Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.